OKIDS GMBH

Their core work

OKIDS GmbH is a Vienna-based specialist in paediatric clinical research, focusing on clinical trial infrastructure and drug development for children, adolescents, and neonates. Their work sits at the intersection of regulatory expertise, clinical trial methodology, and the specific ethical and scientific demands of testing medicines in paediatric populations. They contribute to European networks that coordinate multi-site clinical trials for children — a highly regulated and underserved field where adult trial designs cannot simply be applied. In practice, they likely provide expert advisory services, education and training for clinical staff, and operational support to research consortia building paediatric trial capacity across Europe.

What they specialise in

How they've shifted over time

OKIDS entered H2020 in 2017 through PedCRIN, a foundational infrastructure project for paediatric clinical research — suggesting their earliest EU engagement was about building the network itself. By 2018 they joined c4c, a larger and more operationally focused initiative that extended their involvement into active clinical trial delivery, drug development processes, and patient-facing work with children, adolescents, and neonates. The trajectory is not a change of direction but a deepening: from infrastructure-building to actually running and supporting trials within that infrastructure. With c4c running until 2025, their expertise in this domain has been continuously compounding for nearly a decade.

OKIDS is deepening its specialization in operational paediatric clinical trial delivery, with the c4c project running to 2025 making them a long-term embedded partner in Europe's leading paediatric medicines network — well positioned for future calls in paediatric pharmacology, rare diseases in children, or EU4Health paediatric priorities.

How they like to work

OKIDS participates exclusively as a consortium member — they have not led any H2020 project — suggesting they operate as a specialist contributor within larger, coordinated networks rather than as an initiator. Despite their small size, they have connected with 68 unique partners across 20 countries through just two projects, which reflects the scale of the consortia they join rather than a broad independent network. This points to an organisation that is trusted enough to be included in high-profile, large-consortium projects but does not yet drive the agenda.

OKIDS has built a reach of 68 consortium partners across 20 countries through only two projects, reflecting the large, pan-European nature of both PedCRIN and c4c. Their network is concentrated in the European paediatric clinical research community — academic hospitals, regulatory bodies, and research networks across the EU and associated countries.

What sets them apart

OKIDS occupies a rare niche as an Austrian SME with deep, focused expertise in paediatric clinical trials — a domain where most players are large academic hospitals or regulatory agencies, not small specialist firms. Their dual participation in both the infrastructure project (PedCRIN) and the leading operational network (c4c) means they have visibility across the full paediatric clinical trial pipeline, from site qualification to trial execution and education. For a consortium building a project on children's medicines, rare paediatric diseases, or EU regulatory compliance for paediatric indications, OKIDS offers embedded knowledge and an existing network that would take years to build independently.

Highlights from their portfolio

• c4c
  With EUR 990,230 in EC funding and a run-time through 2025, conect4children is one of Europe's flagship paediatric clinical trial networks — OKIDS' sustained participation signals recognised expertise in this field.
• PedCRIN
  As one of OKIDS' first EU projects, PedCRIN (Paediatric Clinical Research Infrastructure Network) established their entry into the European paediatric research community and laid the groundwork for their c4c involvement.